-
Cabotegravir, sold
under the
brand name
Vocabria among others, is an
antiretroviral medication used for the
treatment and
prevention of HIV/AIDS. It is...
-
Cabotegravir/rilpivirine, sold
under the
brand name Cabenuva, is a co-packaged
antiretroviral medication for the
treatment of HIV/AIDS. It
contains cabotegravir...
- for two new
antiretroviral (ARV) medicines,
rilpivirine (Rekambys) and
cabotegravir (Vocabria), to be used
together for the
treatment of
people with human...
- HIV
through receptive ****l ****. In
December 2021, the FDA
approved cabotegravir (Apretude),
which is an
injectable form of PrEP
manufactured by Viiv...
- In the
European Union,
rilpivirine is
approved in
combination with
cabotegravir for
maintenance treatment of
adults who have
undetectable HIV levels...
- HPTN 083 is a 2016
clinical trial which compares cabotegravir injections with oral use of Emtricitabine/tenofovir as pre-exposure
prophylaxis ("PrEP")...
-
injectable suspension with
extended release of the
antiviral drug
cabotegravir.
Unlike cabotegravir in
tablet form,
Apretude must be
administered via intramuscular...
- [betterĀ sourceĀ needed]
Cabotegravir,
developed by ViiV Healthcare, was
approved in
conjunction with
rilpivirine by the FDA in
January 2021 (
cabotegravir/rilpivirine)...
-
indicates that
antiretroviral drugs,
including lamivudine, doravirine, and
cabotegravir, can
effectively downregulate the
expression of
human endogenous retroviruses...
- &. "Janssen
Announces U.S. FDA
Approval of
CABENUVA (rilpivirine and
cabotegravir), the
First Long-Acting
Regimen for the
Treatment of HIV". www.prnewswire...